CanSino Biologics Inc. (HKG:6185)
Hong Kong · Delayed Price · Currency is HKD 25.80
-1.04 (-3.87%)
Sep 11, 2026, 4:08 PM HKT
CanSino Biologics Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,881 | 12,632 | 11,610 | 12,514 | 27,690 | 66,111 | |
Market Cap Growth | -33.14% | 8.81% | -7.23% | -54.81% | -58.12% | -11.15% |
Enterprise Value | 10,826 | 11,140 | 10,302 | 10,611 | 23,868 | 58,920 |
Last Close Price | 25.80 | 34.92 | 31.50 | 23.55 | 66.75 | 177.89 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 253.26 | 407.26 | - | - | - | 28.13 |
Forward PE | 25.43 | 45.28 | 39.62 | 39.62 | 268.75 | 11.16 |
PS Ratio | 8.33 | 10.63 | 12.89 | 31.81 | 23.68 | 12.53 |
PB Ratio | 2.07 | 2.29 | 2.22 | 2.15 | 3.38 | 6.30 |
P/TBV Ratio | 2.17 | 2.38 | 2.28 | 2.21 | 3.75 | 6.89 |
P/FCF Ratio | - | - | - | - | - | 63.60 |
P/OCF Ratio | - | 124.77 | - | - | - | 26.27 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.59 | 9.37 | 11.44 | 26.97 | 20.41 | 11.16 |
EV/EBITDA Ratio | 81.68 | 130.77 | - | - | - | 25.96 |
EV/EBIT Ratio | - | - | - | - | - | 26.91 |
EV/FCF Ratio | - | - | - | - | - | 56.68 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.19 | 0.26 | 0.41 | 0.51 | 0.37 | 0.16 |
Debt / EBITDA Ratio | 8.10 | 15.68 | - | - | - | 0.74 |
Debt / FCF Ratio | - | - | - | - | - | 1.62 |
Net Debt / Equity Ratio | -0.18 | -0.27 | -0.24 | -0.27 | -0.45 | -0.75 |
Net Debt / EBITDA Ratio | -8.36 | -17.70 | 7.80 | 0.97 | 2.46 | -3.46 |
Net Debt / FCF Ratio | 4.71 | 8.86 | 1.91 | 0.94 | 1.11 | -7.57 |
Asset Turnover | 0.17 | 0.14 | 0.10 | 0.03 | 0.09 | 0.46 |
Inventory Turnover | 0.89 | 0.84 | 0.83 | 1.55 | 1.57 | 2.48 |
Quick Ratio | 3.82 | 3.28 | 2.34 | 1.86 | 2.33 | 2.78 |
Current Ratio | 4.39 | 3.67 | 2.54 | 2.02 | 2.64 | 3.25 |
Return on Equity (ROE) | 0.82% | 0.56% | -7.52% | -31.40% | -12.22% | 26.09% |
Return on Assets (ROA) | -0.60% | -0.73% | -2.52% | -10.36% | -8.03% | 11.97% |
Return on Invested Capital (ROIC) | -1.56% | -2.40% | -9.21% | -43.85% | -48.83% | 108.45% |
Return on Capital Employed (ROCE) | -1.10% | -1.40% | -5.60% | -25.50% | -17.50% | 19.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.39% | 0.25% | -3.47% | -13.05% | -3.71% | 3.55% |
FCF Yield | -1.88% | -1.35% | -5.73% | -13.37% | -11.95% | 1.57% |
Dividend Yield | - | - | - | - | - | 0.55% |
Payout Ratio | 79.20% | 159.68% | - | - | - | 0.74% |
Buyback Yield / Dilution | - | -2.32% | -0.38% | 0.17% | 0.08% | -7.26% |
Total Shareholder Return | - | -2.32% | -0.38% | 0.17% | 0.08% | -6.70% |